Robert W Malone, MD,MS 6/9/2022
The use of COVID vaccines for babies and children is about to be decided based on?Eighteen sitting Congressional members wrote a strong letter to the FDA demanding answers prior to the decision by regulators to approve COVID-19 vaccines for babies and young children aged 6 months to 4 years old. The FDA VRBPAC advisory panel is scheduled to meet on June 15 to discuss authorization and this letter addresses the fact that there are questions and facts that the FDA must consider prior to EUA authorization.
The letter clearly states that COVID-19 poses little risk to babies and young children, that the vaccines have little effectiveness against new variants, that there are many unanswered questions about the safety of the vaccines and that there is evidence of significant adverse events. Therefore, the lawmakers queried the FDA panel as to why these vaccines are necessary for this age cohort.
“The broad approach of the CDC and FDA to date has been a one-size fits all policy—get the vaccine regardless of age, risk factors, the underlying health of the individual, or previous infection,” the members wrote to FDA Commissioner Robert Califf and members of the advisory panel in a June 7 letter obtained by The Epoch Times. “Yet, to date there remain many unanswered questions about these EUA-approved COVID-19 vaccines and only a small percentage of the safety data about these vaccines that are in the possession of the FDA and the manufacturers has been released for review.”
The document states that 68% percent of children aged 1 to 4 have recovered from COVID-19 and that those rates are even higher for older children, according to a cited May 2022 CDC study. The lawmakers note that the rates for natural immunity are even higher now than when the study was conducted, with an estimated 80% of children across all age cohorts being seropositive against COVID. As natural infection yields better protection than vaccination against COVID, plus children who contract COVID-19 have a high survival rate and have little risk of experiencing severe disease, there is little reason to vaccinate at this time.
The lawmakers want the FDA to answer a series of questions before issuing its decision on the EUA requests from Moderna and Pfizer.
The questions below are taken directly from the letter to the FDA (a link to the full letter can be found at the end of the questions). Please make your own interpretations:
1. Why has the FDA been slow to release the hundreds of thousands of pages of data from pre-approved manufacturers studies, post-approval adverse events state, other post-approval manufactures data submitted to the FDA as required by law??
2. What is the FDA doing to expedite the release of this data and when can we expect all of the data in the FDA’S possession on these vaccines to be publicly released?
3. Should the FDA approve EUA COVID vaccines for children under age 5, will the FDA release the data to the public with 14 days of approval that served as the basis for FDA EUA approval? If not, why not? If not within 14 days, when will the FDA release all of this data to the public?
4. When will the FDA and CDC provide the public with more details on those children who have had the most serious adverse outcomes from COVID-19 infections?
More:
https://rwmalonemd.substack.com/p/members-of-congress-demand-answers?s=r